Pay in 4 interest-free payments of $5.69 Learn more
Ships within 48 hours · Estimated delivery Nov 8 - Nov 13
References Teichman SL, et al
Retatrutide is an investigational once-weekly injectable triple agonist that simultaneously activates GLP-1, GIP, and glucagon receptors, targeting appetite, glucose metabolism, and energy expenditure through a single agent
They are also prescribed in patients with higher A1c levels, i.e., 1.5% over target, or in patients who do not reach their target within 3 months
Staying well-hydrated can help reduce this risk
Semaglutide is available under the brand names Ozempic and Wegovy
US$ 29.26
US$ 27.75
US$ 24.90
